TIGIT (M6223 Biosimilar) Recombinant Monoclonal Antibody
-
貨號(hào):CSB-RA675446MB12HU
-
規(guī)格:¥83486
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:TIGIT (M6223 Biosimilar Antibody)重組單克隆抗體是一種針對(duì)TIGIT(T細(xì)胞免疫球蛋白和ITIM結(jié)構(gòu)域蛋白)靶點(diǎn)開發(fā)的科研用生物試劑,專為生命科學(xué)研究設(shè)計(jì)。該抗體通過(guò)基因工程技術(shù)重組表達(dá),具有高特異性和親和力,能夠精準(zhǔn)識(shí)別并結(jié)合TIGIT蛋白,為免疫調(diào)控機(jī)制研究提供關(guān)鍵工具。 TIGIT作為重要的免疫檢查點(diǎn)分子,主要表達(dá)于T細(xì)胞、NK細(xì)胞等免疫細(xì)胞表面,通過(guò)與配體CD155等相互作用,負(fù)向調(diào)控免疫細(xì)胞活化與功能,在腫瘤免疫逃逸、自身免疫疾病等病理過(guò)程中發(fā)揮重要作用。本產(chǎn)品可用于體外細(xì)胞實(shí)驗(yàn)多種實(shí)驗(yàn)技術(shù),助力研究人員深入探索TIGIT信號(hào)通路的分子機(jī)制及其在疾病發(fā)生發(fā)展中的作用。 該重組單克隆抗體制備過(guò)程嚴(yán)格遵循標(biāo)準(zhǔn)化流程,確保批次間穩(wěn)定性和實(shí)驗(yàn)結(jié)果的可重復(fù)性。其高純度特性可有效減少非特異性結(jié)合,適用于復(fù)雜生物樣本的檢測(cè)與分析。研究人員可利用該抗體開展TIGIT表達(dá)水平檢測(cè)、受體-配體相互作用分析、免疫細(xì)胞功能調(diào)控等課題,為開發(fā)新型免疫治療策略提供實(shí)驗(yàn)基礎(chǔ)。 作為科研工具,本產(chǎn)品僅限實(shí)驗(yàn)室研究使用,不可用于臨床診斷或治療。通過(guò)特異性靶向TIGIT,該抗體為揭示免疫調(diào)節(jié)網(wǎng)絡(luò)、開發(fā)靶向免疫療法的前期研究提供有力支持,推動(dòng)免疫學(xué)領(lǐng)域基礎(chǔ)研究與轉(zhuǎn)化醫(yī)學(xué)的發(fā)展。
-
Uniprot No.:
-
基因名:
-
別名:M6223 research-grade biosimilar; M-6223 research-grade biosimilar ;TIGIT antibody; VSIG9 antibody; VSTM3 antibody; T-cell immunoreceptor with Ig and ITIM domains antibody; V-set and immunoglobulin domain-containing protein 9 antibody; V-set and transmembrane domain-containing protein 3 antibody
-
反應(yīng)種屬:Human
-
免疫原:Recombinant Human TIGIT protein
-
免疫原種屬:Homo sapiens (Human)
-
標(biāo)記方式:Non-conjugated
-
克隆類型:Monoclonal
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:0.01M PBS,pH7.4
-
產(chǎn)品提供形式:Liquid
-
應(yīng)用說(shuō)明:Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲(chǔ)存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:3-4 weeks
-
用途:It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能:Binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.
-
基因功能參考文獻(xiàn):
- The activation of PD-1 and TIGIT may exert negative regulatory effects and inhibit the immune response to cancer cells, resulting in immune escape of cancer cells. PMID: 30262800
- These findings highlight the importance of the TIGIT/CD226/PVR axis as an immune checkpoint barrier that could hinder future "cure" strategies requiring potent HIV-specific CD8(+) T cells PMID: 28084312
- High expression of TIGIT and Helios identifies CD4+ T cells with impaired immunological functions, primarily among patients with an advanced stage of Sezary syndrome. PMID: 27592800
- Natural killer cells and cytotoxic T cells express both TIGIT and DNAM-1 receptors, and in certain cases their effector functions are dictated by TIGIT or DNAM-1 signaling. Agonist and antagonist antibodies targeting either TIGIT or DNAM-1 present many therapeutic options for diseases spanning from cancer to auto-immunity. (Review) PMID: 28035916
- TIGIT contributes to functional T-cell impairment and associates with poor clinical outcome in acute myelogenous leukemia. The study suggests that blockade of TIGIT to restore T-cell function and antitumor immunity may represent a novel effective leukemia therapeutic. PMID: 26763253
- Blimp-1 binds to the promoters of PD-1 and TIGIT and positively regulates their expression in patients with acute myeloid leukemia. PMID: 28629373
- Data show that gastric cancer cells inhibit T-cell metabolism through CD155/TIGIT signaling. PMID: 28883004
- Our data provide important structural and biochemical determinants responsible for the recognition of nectin-2 by TIGIT. PMID: 27978489
- TIGIT is a powerful negative regulator of CD4(+) T cells in systemic lupus erythematosus. PMID: 28108989
- TIGIT signaling in NK cells after MDSC coculture led to a decrease in the phosphorylation of ZAP70/Syk and ERK1/2. PMID: 27503932
- energetic basis for the TIGIT/nectin-2 interaction and revealed that an "aromatic key" of nectin-2 is critical for this interaction, whereas variations in the lock were tolerated. PMID: 28515320
- TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. PMID: 26250578
- implying that TIGIT exerts immunosuppressive effects by competing with DNAM-1 for the same ligand, CD155 PMID: 26842126
- These findings identify TIGIT as a novel marker of dysfunctional HIV-specific T cells PMID: 26741490
- This study shows that HBZ-induced TIGIT plays a pivotal role in attenuating host immune responses and shaping a microenvironment favorable to human T-cell leukemia virus type 1. PMID: 26735971
- a novel mechanism that links TIGIT expression with NK-cell functional heterogeneity, and this mechanism might partially explain why individuals have different susceptibilities to infection, autoimmune disease, and cancer. PMID: 26171588
- Human regulatory T cells expressing the receptors TIGIT and CD226 display widely divergent phenotypes in regard to expansion and activation. PMID: 25994968
- TIGIT and PD-1 blockade additively increased proliferation, cytokine production, and degranulation of tumor-antigen-specific CD8 T cells and CD8 TILs. TIGIT and PD-1 regulate the expansion and function of these T cells in melanoma. PMID: 25866972
- The results identify a bacterium-dependent, tumor-immune evasion mechanism in which tumors exploit the Fap2 protein of F. nucleatum to inhibit immune cell activity via TIGIT. PMID: 25680274
- Findings suggest that TIGIT is a key checkpoint inhibitor of chronic antiviral and antitumor responses through impairing CD226 function when disrupting its homodimerization. PMID: 25465800
- TIGIT/PVR ligation signaling mediates suppression of IFN-gamma production via the NF-kappaB pathway. PMID: 24817116
- TIGIT is phosphorylated at its cytoplasmic tail after its ligation with PVR. PMID: 23154388
- The Tim-3 pathway appears to control regulatory (Treg) and effector T cell balance via altering cell proliferation and apoptosis during hepatitis C virus infection. PMID: 22706088
- TIGIT can inhibit T cell functions by competing with CD226 and can also directly inhibit T cells in a T cell-intrinsic manner. PMID: 22427644
- data suggest a cis-trans receptor clustering mechanism for cell adhesion and signaling by the TIGIT/PVR complex and provide structural insights into how the PVR family of immunoregulators function PMID: 22421438
- that soluble Vstm3 attenuates T-cell responses in vitro and in vivo PMID: 21416464
- TIGIT exerts immunosuppressive effects by binding to poliovirus receptor and modulating cytokine production by dendritic cells. PMID: 19011627
- a novel immunoreceptor, Washington University Cell Adhesion Molecule, which is expressed on human follicular B helper T cells, was described. PMID: 19197944
- TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition. PMID: 19815499
顯示更多
收起更多
-
亞細(xì)胞定位:Cell membrane; Single-pass type I membrane protein.
-
組織特異性:Expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level).
-
數(shù)據(jù)庫(kù)鏈接:
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
-
-
-
-
-















